Increasing survivors of anthracycline-related cardiomyopathy with breast cancer in trastuzumab era: thirty-one-year trends in a Japanese Community.
Anthracycline
Cardiotoxicity
Human epidermal growth factor receptor type 2
Secular trend
Trastuzumab
Journal
Breast cancer (Tokyo, Japan)
ISSN: 1880-4233
Titre abrégé: Breast Cancer
Pays: Japan
ID NLM: 100888201
Informations de publication
Date de publication:
13 Aug 2024
13 Aug 2024
Historique:
received:
19
04
2024
accepted:
01
08
2024
medline:
14
8
2024
pubmed:
14
8
2024
entrez:
14
8
2024
Statut:
aheadofprint
Résumé
Trastuzumab has improved breast cancer (BC) prognosis and reduced anthracycline use. However, the characteristic changes of anthracycline-related cardiomyopathy (ARCM) in patients with BC remain unclear. We aimed to update our understanding of ARCM in the trastuzumab era. This retrospective observational cohort study included 2959 patients with BC treated with anthracyclines at three regional cancer centers in Niigata City between 1990 and 2020. Seventy-five patients (2.5%) developed ARCM and were categorized into two groups: pre- 2007 (early phase) and post-2007 (late phase), corresponding to before and during the trastuzumab era in Japan. ARCM incidence peaked at 6% in the 1990s, then decreased and stabilized at 2% until the 2010s. Survivors of anthracycline-treated BC increased more rapidly in the late phase, with four times as many patients with ARCM compared to the end of the early phase (26 and six, respectively). Although the rate of change in accumulation from the early phase to the late phase was slight in the anthracycline-treated BC group, it was more pronounced in the ARCM group (P < 0.001). Mean anthracycline use in the late phase was significantly lower than in the early phase (307 vs. 525 mg/m HER2-positive patients with ARCM receiving trastuzumab therapy had a better prognosis than HER2-positive and HER2-negative patients with ARCM not receiving trastuzumab therapy, and this trend has been increasing in the trastuzumab era. These findings highlight the importance of HER2-targeted treatments in improving prognosis for BC patients with ARCM.
Sections du résumé
BACKGROUND
BACKGROUND
Trastuzumab has improved breast cancer (BC) prognosis and reduced anthracycline use. However, the characteristic changes of anthracycline-related cardiomyopathy (ARCM) in patients with BC remain unclear. We aimed to update our understanding of ARCM in the trastuzumab era.
METHODS
METHODS
This retrospective observational cohort study included 2959 patients with BC treated with anthracyclines at three regional cancer centers in Niigata City between 1990 and 2020. Seventy-five patients (2.5%) developed ARCM and were categorized into two groups: pre- 2007 (early phase) and post-2007 (late phase), corresponding to before and during the trastuzumab era in Japan.
RESULTS
RESULTS
ARCM incidence peaked at 6% in the 1990s, then decreased and stabilized at 2% until the 2010s. Survivors of anthracycline-treated BC increased more rapidly in the late phase, with four times as many patients with ARCM compared to the end of the early phase (26 and six, respectively). Although the rate of change in accumulation from the early phase to the late phase was slight in the anthracycline-treated BC group, it was more pronounced in the ARCM group (P < 0.001). Mean anthracycline use in the late phase was significantly lower than in the early phase (307 vs. 525 mg/m
CONCLUSIONS
CONCLUSIONS
HER2-positive patients with ARCM receiving trastuzumab therapy had a better prognosis than HER2-positive and HER2-negative patients with ARCM not receiving trastuzumab therapy, and this trend has been increasing in the trastuzumab era. These findings highlight the importance of HER2-targeted treatments in improving prognosis for BC patients with ARCM.
Identifiants
pubmed: 39138789
doi: 10.1007/s12282-024-01623-0
pii: 10.1007/s12282-024-01623-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA, Minihan A, et al. Breast cancer statistics, 2022. CA Cancer J Clin. 2022;72:524–41.
doi: 10.3322/caac.21754
pubmed: 36190501
Heer E, Harper A, Escandor N, Sung H, McCormack V, Fidler-Benaoudia MM. Global burden and trends in premenopausal and postmenopausal breast cancer: a population-based study. Lancet Glob Health. 2020;8:e1027–37.
doi: 10.1016/S2214-109X(20)30215-1
pubmed: 32710860
Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, et al. Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast. 2022;66:15–23.
doi: 10.1016/j.breast.2022.08.010
pubmed: 36084384
pmcid: 9465273
Yap YS, Lu YS, Tamura K, Lee JE, Ko EY, Park YH, et al. Insights into breast cancer in the east vs the west: a review. JAMA oncol. 2019;5:1489–96.
doi: 10.1001/jamaoncol.2019.0620
pubmed: 31095268
Katanoda K, Hori M, Saito E, Shibata A, Ito Y, Minami T, et al. Updated trends in cancer in Japan: incidence in 1985–2015 and mortality in 1958–2018—a sign of decrease in cancer incidence. J Epidemiol. 2021;31:426–50.
doi: 10.2188/jea.JE20200416
pubmed: 33551387
pmcid: 8187612
Caswell-Jin JL, Sun LP, Munoz D, Lu Y, Li Y, Huang H, et al. Analysis of breast cancer mortality in the US-1975 to 2019. JAMA. 2024;331:233–41.
doi: 10.1001/jama.2023.25881
pubmed: 38227031
pmcid: 10792466
Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol. 2002;13:699–709.
doi: 10.1093/annonc/mdf132
pubmed: 12075737
Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments. Nat Rev Cardiol. 2015;12:547–58.
doi: 10.1038/nrcardio.2015.65
pubmed: 25962976
Padegimas A, Clasen S, Ky B. Cardioprotective strategies to prevent breast cancer therapy-induced cardiotoxicity. Trends Cardiovasc Med. 2020;30:22–8.
doi: 10.1016/j.tcm.2019.01.006
pubmed: 30745071
Popat S, Smith IE. Therapy Insight: anthracyclines and trastuzumab–the optimal management of cardiotoxic side effects. Nat Clin Pract Oncol. 2008;5:324–35.
doi: 10.1038/ncponc1090
pubmed: 18364726
Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol. 2005;23:2900–2.
doi: 10.1200/JCO.2005.05.827
pubmed: 15860848
Onitilo AA, Engel JM, Stankowski RV. Cardiovascular toxicity associated with adjuvant trastuzumab therapy: prevalence, patient characteristics, and risk factors. Ther Adv Drug Saf. 2014;5:154–66.
doi: 10.1177/2042098614529603
pubmed: 25083270
pmcid: 4110857
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials. Lancet. 2023;401:1277–92.
doi: 10.1016/S0140-6736(23)00285-4
Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, et al. De-escalating and escalating treatments for early-stage breast cancer: the St Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2017;28:1700–12.
doi: 10.1093/annonc/mdx308
pubmed: 28838210
pmcid: 6246241
Tada K, Kumamaru H, Miyata H, Asaga S, Iijima K, Ogo E, et al. Characteristics of female breast cancer in japan: annual report of the National Clinical Database in 2018. Breast Cancer. 2023;30:157–66.
doi: 10.1007/s12282-022-01423-4
pubmed: 36547868
Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, André F, Barrios CH, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31:1623–49.
doi: 10.1016/j.annonc.2020.09.010
pubmed: 32979513
Saji S, Hiraoka M, Tokuda Y, Fukui N, Ikeda T. Trends in local therapy application for early breast cancer patients in the Japanese Breast Cancer Society Breast Cancer Registry during 2004–2009. Breast Cancer. 2012;19:1–3.
doi: 10.1007/s12282-011-0308-z
pubmed: 22124993
Anazawa T, Miyata H, Gotoh M. Cancer registries in Japan: National Clinical Database and site-specific cancer registries. Int J Clin Oncol. 2015;20:5–10.
doi: 10.1007/s10147-014-0757-4
pubmed: 25376769
Onishi T, Fukuda Y, Miyazaki S, Yamada H, Tanaka H, Sakamoto J, et al. Practical guidance for echocardiography for cancer therapeutics-related cardiac dysfunction. J Echocardiogr. 2021;19:1–20.
doi: 10.1007/s12574-020-00502-9
pubmed: 33159650
Čelutkienė J, Pudil R, López-Fernández T, Grapsa J, Nihoyannopoulos P, Bergler-Klein J, et al. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). Eur J Heart Fail. 2020;22:1504–24.
doi: 10.1002/ejhf.1957
pubmed: 32621569
The Japanese Breast Cancer Society. The Japanese Breast Cancer Society clinical practice guidelines for breast cancer 2007. Tokyo: KANEHARA & CO., LTD.; 2007. (Japanese).
Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:2768–801.
doi: 10.1093/eurheartj/ehw211
pubmed: 27567406
Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000;342:1077–84.
doi: 10.1056/NEJM200004133421502
pubmed: 10760308
Swain SM, Shastry M, Hamilton E. Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discov. 2023;22:101–26.
doi: 10.1038/s41573-022-00579-0
pubmed: 36344672
Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131:1981–8.
doi: 10.1161/CIRCULATIONAHA.114.013777
pubmed: 25948538
de Azambuja E, Agostinetto E, Procter M, Eiger D, Pondé N, Guillaume S, et al. Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial. ESMO Open. 2023;8: 100772.
doi: 10.1016/j.esmoop.2022.100772
pubmed: 36681013
pmcid: 10044361
Ohtsu H, Shimomura A, Miyazaki S, Yonemoto N, Ueda S, Shimizu C, et al. Cardiotoxicity of adjuvant chemotherapy with trastuzumab: a Japanese claim-based data analysis. Open Heart. 2022;9: e002053.
doi: 10.1136/openhrt-2022-002053
pubmed: 35995458
pmcid: 9403121
Yamshiro H, Iwata H, Masuda N, Yamamoto N, Nishimura R, Ohtani S, et al. Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients. Int J Clin Oncol. 2015;20:709–22.
doi: 10.1007/s10147-015-0785-8
pubmed: 25666483
Banke A, Fosbøl EL, Ewertz M, Videbæk L, Dahl JS, Poulsen MK, et al. Long-term risk of heart failure in breast cancer patients after adjuvant chemotherapy with or without trastuzumab. JACC Heart Fail. 2019;7:217–24.
doi: 10.1016/j.jchf.2018.09.001
pubmed: 30819377
Bostany G, Chen Y, Francisco L, Dai C, Meng Q, Sparks J, et al. Cardiac dysfunction among breast cancer survivors: role of cardiotoxic therapy and cardiovascular risk factors. J Clin Oncol. 2024; p. JCO2301779.
Herrmann J, Lenihan D, Armenian S, Barac A, Blaes A, Cardinale D, Carver J, et al. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J. 2022;43:280–99.
doi: 10.1093/eurheartj/ehab674
pubmed: 34904661
Ramadan MM, Ohno Y, Okura Y, Tanabe N, Suzuki K, Abe A, et al. Systolic dysfunction in urban Japan. Circ J. 2008;72:349–57.
doi: 10.1253/circj.72.349
pubmed: 18296828